[Translation] A single-center, randomized, open-label, two-period, two-crossover design to evaluate the human bioequivalence of a single fasting oral potassium chloride sustained-release tablet in Chinese healthy subjects
以UPSHER-SMITH LABORATORIES INC生产的氯化钾缓释片(KLOR-CON,10mEq(规格:750mg))为参比制剂,以深圳市中联制药有限公司生产的氯化钾缓释片(规格:0.5g)为受试制剂,通过单中心、随机、开放、双周期、双交叉的临床试验设计评价两种制剂在空腹给药条件下的生物等效性。次要目的:观察受试制剂和参比制剂在中国健康受试者中的安全性。
[Translation] Take potassium chloride sustained-release tablets (KLOR-CON, 10mEq (specification: 750mg)) produced by UPSHER-SMITH LABORATORIES INC as the reference preparation, and potassium chloride sustained-release tablets produced by Shenzhen Zhonglian Pharmaceutical Co., Ltd. (specification: 0.5g) is the test preparation, and the bioequivalence of the two preparations under fasting administration conditions is evaluated through a single-center, randomized, open, double-cycle, double-crossover clinical trial design. Secondary objective: To observe the safety of test and reference products in healthy Chinese subjects.